Drug Trial Radar · NCT04940026
Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women
Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Jun 15, 2021
Primary completion
Aug 19, 2021
Study completion Aug 19, 2021
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Female only, from 40 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objectives: * To assess the excretion balance after oral and IV administration of \[14C\]-SAR439859 * To assess PK of total radioactivity, \[14C\] -SAR439859 and its metabolite (M7) after IV administration of \[14C\]-SAR439859 and, PK of radioactivity, SAR439859 and M7 after oral administration of SAR439859 alone or with \[14C\]-SAR439859 * To assess IV clearance and absolute bioavailability of SAR439859 using microdose of \[14C\]-SAR439859 tracer on top of a single tablet oral dose. * To assess relative bioavailability of SAR439859 given as tablet or solution Secondary objectives: * To collect samples in order to assess metabolic profile in plasma and excreta of SAR439859 after oral administration of \[14C\]-SAR439859 as solution, contribution in plasma of SAR439859 and metabolite relative to total radioactivity and identify metabolites (samples will be analyzed according to metabolic analysis plan and results will be documented in a separate report). * To assess safety and tolerance of SAR439859
Conditions
- Breast Cancer
- Healthy Volunteers
Interventions
amcenestrantDrug
Tablet Oral
[14C]-SAR439859 microtracerDrug
Solution for infusion Intravenous
[14C]-SAR439859Drug
Powder for oral solution Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of radioactive dose, SAR439859 and M7 excreted in urine and feces after IV administrationTime frame: Day 1 to Day 6
- Percentage of radioactive dose excreted in urine and feces after oral administrationTime frame: Day 7 up to max Day 44
- Assessment of Pharmacokinetic (PK) parameter: AUC for radioactivity and SAR439859 after IV administrationTime frame: Day 1 to Day 3
- Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after IV administrationTime frame: Day 1 to Day 3
- Assessment of PK parameter: CL for SAR439859 after IV administrationTime frame: Day 1 to Day 3
- Assessment of PK parameter: AUC ratios after IV administrationTime frame: Day 1 to Day 3
- Assessment of PK parameter: Cmax for radioactivity and SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
- Assessment of PK parameter: tmax for radioactivity and SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
- Assessment of PK parameter: AUC for radioactivity and SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
- Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
- Assessment of PK parameter: AUC ratios after oral administrationTime frame: Day 7 to Day 11
- Assessment of PK parameter: Cmax for M7 after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
- Assessment of PK parameter: AUC for M7 after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
- Assessment of PK parameter: t1/2z for M7 after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
- Assessment of PK parameter: Rmet Cmax after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
- Assessment of PK parameter: Rmet AUC after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
- Absolute oral bioavailability of SAR439859Time frame: Day 1 to Day 5, Day 7 to Day 11
- Relative bioavailability of SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational Site Number 8260001
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.